인실리코 Drug Discovery 시장 보고서 : 동향, 예측 및 경쟁 분석(-2030년)

In-Silico Drug Discovery Trends and Forecast

The future of the global in-silico drug discovery market looks promising with opportunities in the contract research organizations, pharmaceutical industry, and academic & research institutes markets. The global in-silico drug discovery market is expected to reach an estimated $5.5 billion by 2030 with a CAGR of 10.2% from 2024 to 2030. The major drivers for this market are rising focus towards reduction of medication errors, increasing adoption of cloud-based applications in drug discovery, and on-going advancements in computational biology.

• Lucintel forecasts that software as a service is expected to witness the highest growth over the forecast period due to its increasing adoption for virtual screening and target fising in the drug discovery procedure.
• Within this market, pharmaceutical industry will remain the largest segment due as in-silico drug discovery helps the pharmaceutical companies to reduce the time and cost of developing new drugs.
• North America will remain the largest region over the forecast period due to increasing R&D expenditure by biopharma company, strong presence of market players, and large patient population suffering from various chronic and infectious diseases in the region.

Emerging Trends in the In-Silico Drug Discovery Market

There are several emerging trends in the In-Silico Drug Discovery market, which mark the changing face of the drug development and research landscape.

• AI and Machine Learning Integration: Artificial intelligence and machine learning have started to be integrated more and more into drug development processes, further enhancing predictive accuracy and optimization of drug design. These technologies have been used to analyze large datasets and predict the nature of drug interactions more accurately.
• Personalized Medicine: Interest in personalized medicine is driven by advances in genomics and bioinformatics. In-silico models for tailoring drug discovery and development to individual genetic profiles can enhance efficacy while minimizing adverse effects.
• Cloud-Based Platforms: Cloud-based platforms are of increasing interest due to their scalable delivery of in-silico drug discovery solutions. Such platforms enable collaboration, data sharing, and computational analysis that further streamline drug discovery.
• High-Performance Computing: The application of high-performance computing is growing fast, which allows for complex simulations and large-scale data analysis. These will enable more detailed and correct in-silico modeling, accelerating drug discovery and development.
• Integration of Multi-Omics Data: Integration of multi-omics data, such as genomics, proteomics, and metabolomics, is a rapidly developing area in in-silico drug discovery. These trends allow for a more in-depth understanding of biological systems and enhance the identification of potential drug targets.

This will continue to reshape the face of the In-Silico Drug Discovery market by further developing the technological capabilities, precision, and efficiency of drug discovery processes.

Recent Developments in the In-Silico Drug Discovery Market

Recent developments in the In-Silico Drug Discovery market have painted a picture of great advancement and innovation. These are the factors that contribute to significant growth in methodology for drug discovery.

• AI Algorithm Development: New algorithms, such as developing machine learning algorithms for AI, are being developed to improve predictive modeling and virtual screening. This increases the rate and accuracy of identification of drug candidates and accelerates the processes involved in drug discovery.
• Integration of Genomic Data: The integration of genomic data moves on to more precise in-silico models for identification of drug targets and personalized medicine approaches. This trend contributes to the development of therapies depending on genetic information.
• Increase in Cloud-Based Solutions: Cloud-based solutions are very common today, offering scalable and flexible platforms for in-silico drug discovery. These solutions enable the collaboration of researchers and pharmaceutical companies through data sharing.
• Improvement of high-performance computing: Improvement in high-performance computing technologies can allow complex simulations and data analysis, thus supporting detailed in-silico modeling and speeding up drug development processes.
• Development of Tools for Multi-Omics Integration: Approaches toward integrating multi-omics data are rapidly improving, providing comprehensive views into biological systems. Such development enhances the capability for the identification of drug targets and development of effective therapies.

These factors influence the In-Silico Drug Discovery market by improving technological capabilities, increasing applications, and thus accelerating the process for drug discovery.

Strategic Growth Opportunities for In-Silico Drug Discovery Market

The In-Silico Drug Discovery market presents various strategic growth opportunities from major applications. Proper identification of opportunities and building on them would facilitate further expansion and innovations in this market.

• AI-driven drug discovery: The development of AI-driven platforms will increase predictive modeling and virtual screening. Due to that fact, drug discovery becomes more efficient while development costs decrease.
• Personalized Medicine Solutions: Growth is seen in the development of in-silico models for personalized medicine. Companies can create therapies with much higher effectiveness by tailoring drug discovery at an individual genetic level.
• Cloud-Based Drug Discovery Platforms: The growth of cloud-based platforms presents an opportunity to provide scalable and accessible drug discovery solutions. These platforms support collaboration and data sharing among global research teams.
• High-Performance Computing Services: The requirement for complex simulations and large-scale data analysis in drug discovery can be addressed by leveraging high-performance computing services. It helps perform extensive in-silico modeling and accelerates the development of drugs.
• Multi-omics Integration Technologies: Investments in integrated multi-omics data technologies create opportunities that can bring more value to the process of drug target identification and development. This approach provides a much deeper understanding of biological systems, which will significantly improve the outcomes related to drug discovery.

These emerging opportunities consolidate growth in the In-Silico Drug Discovery market through continued technological development, expanded service offerings, and the furtherance of innovative approaches toward drug development.

In-Silico Drug Discovery Market Driver and Challenges

It is constantly shaped by the facets of technology, economics, and regulation. Further, it describes drivers and challenges associated with the market and how to overcome them.

The factors responsible for driving the in-silico drug discovery market include:

1. Technological advancements: Innovation in AI, machine learning, and high-performance computing-a strong driver of growth in in-silico drug discovery. These technologies enhance predictive accuracy and streamline the process of drug discovery.

2. Increasing R&D Investment: Growing investment in research and development is one of the factors increasing the growth rate in the field of in-silico drug discovery. This investment supports new tool and technology development, hence enhancing efficiency in drug discovery.

3. Demand for Personalized Medicine: The concept of personalized medicine promotes the demand for in-silico models that individualize drug discovery concerning the person's genetic makeup. This offers better treatment with reduced side effects.

4. Cloud Adoption: With widening adoption, cloud computing enables access to scalable and agile platforms for drug discovery. Cloud-based solutions facilitate collaboration, data sharing, and computation analyses.

5. Integration of Multi-omics Data: Such integration thereby allows in-silico drug discovery with a holistic understanding of biological systems. This trend brings better identification and development of drug targets more accurately.

Challenges in the in-silico drug discovery market are:

1. Data Privacy and Security: One of the key challenges with in-silico drug discovery is ensuring privacy and security regarding sensitive data used. The protection of intellectual property and patient data is of utmost importance for building trust and ensuring compliance.

2. Complexity of Integration: In any case, a variety of data sources and technologies being integrated into cohesive in-silico models pose a very complex challenge. Compatibility issues are raised and need to be integrated into a seamless flow of data continuously.

3. High Costs of Advanced Technologies: Organizations often find that huge expenses related to advanced technologies and computational resources are a big obstacle. This balances out with the cost relative to the benefits derived in in-silico drug discovery.

These drivers and challenges are driving the In-Silico Drug Discovery market, shaping it with factors that influence growth, innovation, and overall market dynamics.

List of In-Silico Drug Discovery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies in-silico drug discovery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the in-silico drug discovery companies profiled in this report include-

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

In-Silico Drug Discovery by Segment

The study includes a forecast for the global in-silico drug discovery by type, target therapeutic area, workflow, end use, and region.

In-Silico Drug Discovery Market by Type [Analysis by Value from 2018 to 2030]:

• Software as a service
• Consultancy as a service
• Software

In-Silico Drug Discovery Market by Target Therapeutic Area [Analysis by Value from 2018 to 2030]:

• Human Immunodeficiency Virus (HIV)
• Infectious diseases
• Metabolic disorders
• Mental disorders
• Musculoskeletal disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Others

In-Silico Drug Discovery Market by Workflow [Analysis by Value from 2018 to 2030]:

• Discovery
• Target identification
• Reverse docking
• Bioinformatics
• Protein structure prediction
• Target validation
• Lead discovery
• Pharmacophore
• Others

In-Silico Drug Discovery Market by End Use [Analysis by Value from 2018 to 2030]:

• Contract research organizations
• Pharmaceutical industry
• Academic & research institutes
• Others

In-Silico Drug Discovery Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the In-Silico Drug Discovery Market

In-silico drug discovery has become one of the fast-emerging fields with the integration of AI, machine learning, and big data analytics. These are transforming the processes of drug discovery to increase predictive accuracy and reduce time and cost. Key Developments: United States, China, Germany, India, and Japan reflect these international trends as increased investments and technological innovations have been observed in the area.

• United States: In the US, big strides are being taken in AI and machine learning. Due to that, predictive modeling and virtual screening within the realm of drug search have gotten tremendous improvements. Advanced algorithms, big data on plight and target biology, and other factors have increasingly been employed by firms to identify potential drug candidates more correctly and fast, hence promoting quicker and affordable ways of developing drugs.
• China: China also emphasizes integrating AI with bioinformatics for accelerated drug discovery. Recent years have seen the development of sophisticated computational tools that predict drug interaction and efficacy, a step toward attaining the country's dream of becoming a global leader in pharmaceutical innovation.
• Germany: High-performance computing is increasingly applied to the process of drug discovery in Germany. It bases its hopes on good R&D infrastructure for the development of new in-silico models that help to improve drug target identification and optimization processes in drug design.
• India: India is focused on the democratization of access to in-silico drug discovery tools, a trend towards cloud-based platforms, and partnerships with global firms to build its national capabilities around drug development and research.
• Japan: Japan is enhancing its in-silico drug development platform by incorporating genomics and AI. The immediate focus of the country is to use such technologies for precision medicine and acceleration of targeted therapies.

Features of the Global In-Silico Drug Discovery Market

Market Size Estimates: In-silico drug discovery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: In-silico drug discovery market size by various segments, such as by type, target therapeutic area, workflow, end use, and region in terms of value ($B).

Regional Analysis: In-silico drug discovery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, target therapeutic areas, workflow, end uses, and regions for the in-silico drug discovery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the in-silico drug discovery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q1. What is the in-silico drug discovery market size?

Answer: The global in-silico drug discovery market is expected to reach an estimated $5.5 billion by 2030.

Q2. What is the growth forecast for in-silico drug discovery market?

Answer: The global in-silico drug discovery market is expected to grow with a CAGR of 10.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the in-silico drug discovery market?

Answer: The major drivers for this market are rising focus towards reduction of medication errors, increasing adoption of cloud-based applications in drug discovery, and on-going advancements in computational biology.

Q4. What are the major segments for in-silico drug discovery market?

Answer: The future of the in-silico drug discovery market looks promising with opportunities in the contract research organizations, pharmaceutical industry, and academic & research institutes markets.

Q5. Who are the key in-silico drug discovery market companies?

Answer: Some of the key in-silico drug discovery companies are as follows:

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

Q6. Which in-silico drug discovery market segment will be the largest in future?

Answer: Lucintel forecasts that software as a service is expected to witness the highest growth over the forecast period due to its increasing adoption for virtual screening and target fising in the drug discovery procedure.

Q7. In in-silico drug discovery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing R&D expenditure by biopharma company, strong presence of market players, and large patient population suffering from various chronic and infectious diseases in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the in-silico drug discovery market by type (software as a service, consultancy as a service, and software), target therapeutic area (human immunodeficiency virus (HIV), infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, and others), workflow (discovery, target identification, reverse docking, bioinformatics, protein structure prediction, target validation, lead discovery, pharmacophore, and others), end use (contract research organizations, pharmaceutical industry, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global In-Silico Drug Discovery Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global In-Silico Drug Discovery Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global In-Silico Drug Discovery Market by Type
  • 3.3.1: Software as a service
  • 3.3.2: Consultancy as a service
  • 3.3.3: Software
• 3.4: Global In-Silico Drug Discovery Market by Target Therapeutic Area
  • 3.4.1: Human Immunodeficiency Virus (HIV)
  • 3.4.2: Infectious diseases
  • 3.4.3: Metabolic disorders
  • 3.4.4: Mental disorders
  • 3.4.5: Musculoskeletal disorders
  • 3.4.6: Neurological disorders
  • 3.4.7: Oncological disorders
  • 3.4.8: Respiratory disorders
  • 3.4.9: Others
• 3.5: Global In-Silico Drug Discovery Market by Workflow
  • 3.5.1: Discovery
  • 3.5.2: Target identification
  • 3.5.3: Reverse docking
  • 3.5.4: Bioinformatics
  • 3.5.5: Protein structure prediction
  • 3.5.6: Target validation
  • 3.5.7: Lead discovery
  • 3.5.8: Pharmacophore
  • 3.5.9: Others
• 3.6: Global In-Silico Drug Discovery Market by End Use
  • 3.6.1: Contract research organizations
  • 3.6.2: Pharmaceutical industry
  • 3.6.3: Academic & research institutes
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global In-Silico Drug Discovery Market by Region
• 4.2: North American In-Silico Drug Discovery Market
  • 4.2.1: North American In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.2.2: North American In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.3: European In-Silico Drug Discovery Market
  • 4.3.1: European In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.3.2: European In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.4: APAC In-Silico Drug Discovery Market
  • 4.4.1: APAC In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.4.2: APAC In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.5: ROW In-Silico Drug Discovery Market
  • 4.5.1: ROW In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.5.2: ROW In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global In-Silico Drug Discovery Market by Type
  • 6.1.2: Growth Opportunities for the Global In-Silico Drug Discovery Market by Target Therapeutic Area
  • 6.1.3: Growth Opportunities for the Global In-Silico Drug Discovery Market by Workflow
  • 6.1.4: Growth Opportunities for the Global In-Silico Drug Discovery Market by End Use
  • 6.1.5: Growth Opportunities for the Global In-Silico Drug Discovery Market by Region
• 6.2: Emerging Trends in the Global In-Silico Drug Discovery Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global In-Silico Drug Discovery Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global In-Silico Drug Discovery Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Curia
• 7.2: Certara
• 7.3: Charles River Laboratories
• 7.4: Chemical Computing
• 7.5: GenScript
• 7.6: Sygnature Discovery
• 7.7: Abzena